News
XRTX
0.9201
-5.03%
-0.0487
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 3d ago
Weekly Report: what happened at XRTX last week (1012-1016)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/12 17:05
Weekly Report: what happened at XRTX last week (1005-1009)?
Weekly Report · 10/12 10:22
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 10/09 21:05
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 10/09 17:05
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 10/09 12:05
XORTX Plans Canadian Trial Of Gout Drug XORLO To Support Future U.S. NDA Filing; Stock Up
NASDAQ · 10/09 10:20
XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
Benzinga · 10/09 06:50
Closing Bell Movers: Telecom stocks fall on SpaceX spectrum license
TipRanks · 10/08 23:45
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 10/08 21:05
XORTX Moves to File Health Canada Trial Application for XRx-026 Gout Program
TipRanks · 10/08 20:27
Xortx Therapeutics outlines anticipated clinical trial application for XRx-026
TipRanks · 10/08 20:05
Weekly Report: what happened at XRTX last week (0928-1002)?
Weekly Report · 10/05 10:21
Weekly Report: what happened at XRTX last week (0921-0925)?
Weekly Report · 09/28 10:16
Weekly Report: what happened at XRTX last week (0914-0918)?
Weekly Report · 09/21 10:17
Biotech Stocks In Focus - IMCC +245%, XRTX +12%, SILO, BFRI
NASDAQ · 09/18 19:27
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 09/18 17:05
XORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A Year
NASDAQ · 09/18 12:35
Xortx Therapeutics announces planned FDA IND submission for XRx-026
TipRanks · 09/18 12:15
More
Webull provides a variety of real-time XRTX stock news. You can receive the latest news about Xortx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.